Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMSES: Palforzia in peanut-allergic children
NCT03126227Phase 3Completed
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in peanut allergy comparing AR101 with Placebo (2 arms). Primary endpoint: Frequency of Treatment Emergent Adverse Events, Including Serious Adverse Events at 6 months. Started May 2017; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03126227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126227.